Kiniksa Pharmaceuticals, a clinical-stage biotech developing treatments for autoinflammatory and autoimmune conditions, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Lexington, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol KNSA. Kiniksa Pharmaceuticals filed confidentially on February 27, 2018. Goldman Sachs and J.P. Morgan are the joint bookrunners on the deal. No pricing terms were disclosed.
